Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

35.0K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.0K
Hypothesis: Accept or Fail to Reject?01:17

Hypothesis: Accept or Fail to Reject?

27.3K
The outcome of any hypothesis testing leads to rejecting or not rejecting the null hypothesis. This decision is taken based on the analysis of the data, an appropriate test statistic, an appropriate confidence level, the critical values, and P-values. However, when the evidence suggests that the null hypothesis cannot be rejected, is it right to say, 'Accept' the null hypothesis?
There are two ways to indicate that the null hypothesis is not rejected. 'Accept' the null...
27.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The diagnostic role of transbronchial lung cryobiopsy in inflammatory myeloid neoplasms.

Respiratory medicine and research·2026
Same author

Lung involvement of myeloid-lymphoid neoplasm with eosinophilia.

American journal of respiratory and critical care medicine·2025
Same author

Cluster analysis for clinical, radiological, and histopathological profiling in chronic pulmonary graft-versus-host disease.

European journal of internal medicine·2025
Same author

EBUS/EUS-guided lymph nodal gadolinium injection and MRI of the chest in diagnosis of abnormal lymphatic drainage. A case series.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2025
Same author

Indwelling pleural catheters and medical thoracoscopy.

Breathe (Sheffield, England)·2025
Same author

Bispecific T-Cell Engagers-Induced Interstitial Lung Disease: Two Case Reports Confirmed by Transbronchial Lung Cryobiopsy.

Respiration; international review of thoracic diseases·2025

Related Experiment Video

Updated: May 10, 2025

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
02:46

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

3.4K

"Regression to the truth": lessons learned from negative IPF trials.

Athina Trachalaki1,2, Anna L Lindahl3,2, Simone Petrarulo4,2

  • 1Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London, UK.

Breathe (Sheffield, England)
|April 21, 2025
PubMed
Summary
This summary is machine-generated.

Idiopathic pulmonary fibrosis (IPF) drug development faces challenges, as late-stage trials for new therapies like zinpentraxin alfa, ziritaxestat, and pamrevlumab have failed. Addressing pitfalls in trial design and embracing innovative methods are crucial for future IPF treatment success.

More Related Videos

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.6K

Related Experiment Videos

Last Updated: May 10, 2025

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
02:46

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

3.4K
A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.6K

Area of Science:

  • Pulmonology
  • Clinical Pharmacology
  • Biostatistics

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited effective treatments, despite existing therapies like pirfenidone and nintedanib.
  • Recent late-stage clinical trials of novel IPF therapies have yielded disappointing results, highlighting challenges in drug development.
  • The phenomenon of 'regression to the truth' suggests that positive early-phase trial findings may not always translate to late-stage efficacy.

Purpose of the Study:

  • To examine three pivotal late-stage clinical trials of novel IPF therapies (zinpentraxin alfa, ziritaxestat, pamrevlumab) that failed to meet their primary endpoints.
  • To identify common pitfalls and challenges in IPF drug development based on these trial failures.
  • To propose innovative approaches and methodologies to improve the robustness and success rate of future IPF clinical trials.

Main Methods:

  • Review and analysis of three specific late-stage clinical trials for novel IPF therapies.
  • Identification of common issues in trial design, including sample size, endpoint selection, and integration of background therapies.
  • Exploration of advanced statistical and trial design methodologies for future drug development.

Main Results:

  • Zinpentraxin alfa, ziritaxestat, and pamrevlumab trials failed in late-stage development, indicating significant hurdles in translating promising early results.
  • Key challenges identified include inadequate phase II sample sizes, over-reliance on surrogate endpoints (e.g., forced vital capacity), and difficulties managing concurrent antifibrotic treatments.
  • These failures underscore the 'regression to the truth' in drug development, where early efficacy signals may not be substantiated in larger, later-phase studies.

Conclusions:

  • Late-stage failures in IPF drug development necessitate a re-evaluation of current clinical trial strategies.
  • Implementing adaptive trial designs, Bayesian statistics, and composite endpoints can enhance trial rigor.
  • Platform trials offer a potential avenue to accelerate the testing of multiple IPF therapies, ultimately aiming to improve patient outcomes and survival in IPF.